Recurrence risk in small, node-negative, early breast cancer: A multicenter retrospective analysis

Journal of Cancer Research and Clinical Oncology

Volumn 139, Issue 5, 2013, Pages 853-860

  Gamucci, T ^a   Vaccaro, A ^a   Ciancola, F ^a   Pizzuti, L ^b   Sperduti, I ^b   Moscetti, L ^c   Longo, F ^d   Fabbri, M A ^c   Giampaolo, M A ^a   Mentuccia, L ^a   Di Lauro, L ^b   Vici, P ^b  

^a ASL Frosinone   (Italy)

^b REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^c BELCOLLE HOSPITAL   (Italy)

^d SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Node negative; Prognostic biological factors; Recurrence risk; Small breast cancer

Indexed keywords

AROMATASE INHIBITOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; KI 67 ANTIGEN; TAMOXIFEN; TAXANE DERIVATIVE;

ADJUVANT THERAPY; ADULT; AGED; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER GRADING; CANCER PATIENT; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER SIZE; CANCER STAGING; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FEMALE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MULTICENTER STUDY (TOPIC); OVERALL SURVIVAL; PRIORITY JOURNAL; RECURRENCE RISK; RETROSPECTIVE STUDY; RISK ASSESSMENT; SURVIVAL RATE; SURVIVAL TIME; TRIPLE NEGATIVE BREAST CANCER;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM STAGING; PROGNOSIS; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; RECURRENCE; RETROSPECTIVE STUDIES; RISK; SURVIVAL ANALYSIS; YOUNG ADULT;

EID: 84876296473     PISSN: 01715216     EISSN: 14321335     Source Type: Journal    
DOI: 10.1007/s00432-013-1388-2     Document Type: Article

References (36)

1. Amar S, McCullough AE, Tan W et al (2010) Prognosis and outcome of small (≥1 cm), node-negative breast cancer on the basis of hormonal and HER-2 status. Oncologist 15:1043-1049
2. Banerjee S, Smith IE (2010) Management of small HER2-positive breast cancers. Lancet Oncol 11:1193-1199
3. Benson JR, Jatoi I, Keisch M, Esteva FJ, Makris A, Jordan VC (2009) Early breast cancer. Lancet 373:1463-1479
4. Black D, Younger J, Martei Y et al (2006) Recurrence risk in T1a-b, node negative, HER2 positive breast cancer. [abstract 2037]. Breast Cancer Res Treat 100:S92
5. Buzdar AU, Ibrahim NK, Francis D, Booser DJ et al (2005) Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2 positive operable breast cancer. J Clin Oncol 23:3676-3685
6. Cancello G, Maisonneuve P, Rotmensz N et al (2011) Prognosis in women with small (T1mic, T1a, T1b) node-negative operable breast cancer by immunohistochemically selected subtypes. Breast Cancer Res Treat 127:713-720
7. Chia SK, Speers CH, Bryce CJ, Hayes MM, Olivotto IA (2004) Ten-year outcomes in a population-based cohort of node-negative, lymphatic, and vascular invasion-negative early breast cancers without adjuvant systemic therapies. J Clin Oncol 22:1630-1637
8. Colleoni M, Rotmensz N, Peruzzotti G et al (2004) Minimal and small size invasive breast cancer with no axillary lymph node involvement: the need for tailored adjuvant therapies. Ann Oncol 15:1633-1639
9. Curigliano G, Viale G, Bagnardi V et al (2009) Clinical relevance of HER2 overexpression/amplification in patients with small tumor size and node-negative breast cancer. J Clin Oncol 27:5693-5699
10. Foulkes WD, Reis-Filho JS, Narod SA (2010) Tumor size and survival in breast cancer-a reappraisal. Nat Rev Clin Oncol 7:348-353
11. Garassino I, Gullo G, Orefice S et al (2009) Outcome of T1N0M0 breast cancer in relation to St. Gallen risk assignment criteria for adjuvant therapy. Breast 18:263-266
12. Gnant M, Harbeck N, Thomssen C, St. Gallen (2011) Summary of the consensus discussion. Breast Care (Basel) 6:136-141
13. Goldhirsch A, Wood WC, Coates AS et al (2011) Strategies for subtypes-dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer. Ann Oncol 22:1736-1747
14. Gonzalez-Angulo AM, Litton JK, Broglio KR et al (2009) High risk of recurrence for patients with breast cancer who have human epidermal growth factor receptor 2-positive, node-negative tumors 1 cm or smaller. J Clin Oncol 27:5700-5706
15. Hanrahan EO, Gonzalez-Angulo AM, Giordano SH et al (2007) Overall survival and cause-specific mortality of patients with stage T1a, bN0M0 breast carcinoma. J Clin Oncol 25:4952-4960
16. Ho AY, Gupta G, King TA et al (2012) Favorable prognosis in patients with T1a/T1bN0 triple-negative breast cancers treated with multimodality therapy. Cancer 118:4944-4952
17. Horio A, Fujita T, Hayashi H et al (2012) High recurrence risk and use of adjuvant trastuzumab in patients with small, HER2-positive, node-negative breast cancers. Int J Clin Oncol 17:131-136
18. Ichizawa N, Fukutomi T, Iwamoto E, Akashi-Tanaka S (2002) Long-term results of T1a, T1b and T1c invasive breast carcinomas in Japanese women: validation of the UICC T1 subgroup classification. Jpn Clin Oncol 32:108-109
19. Joensuu H, Kellokumpu-Lehtinen PL, Bono P et al (2006) Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med 354:809-820
20. Kaplan HG, Malmgren JA, Atwood M (2009) T1N0 triple negative breast cancer: risk of recurrence and adjuvant chemotherapy. Breast J 15:454-460
21. Kelly CM, Pritchard KI, Trudeau M, Andreopoulou E, Hess K, Pusztai L (2011) Coping with uncertainty: T1a, bN0M0 HER2-positive breast cancer, do we have a treatment threshold? Ann Oncol 22:2387-2393
22. Kwon JH, Kim YJ, Lee KW et al (2010) Triple negativity and young age as prognostic factors in lymph node-negative invasive ductal carcinoma of 1 cm or less. BMC Cancer 10:557
23. Lai HW, Kuo SJ, Chen LS et al (2011) Prognostic significance of triple negative breast cancer at tumor size 1 cm and smaller. Eur J Surg Oncol 37:18-24
24. Livi L, Meattini I, Saieva C et al (2012) Prognostic value of positive human epidermal growth factor receptor 2 status and negative hormone status in patients with T1a/T1b, lymph node-negative breast cancer. Cancer 118:3236-3243
25. McArthur HL, Mahoney KM, Morris PG et al (2011) Adjuvant trastuzumab with chemotherapy is effective in women with small, node-negative, HER2-positive breast cancer. Cancer 117:5461-5468
26. Mook S, Knauer M, Bueno-de-Mesquita JM et al (2010) Metastatic potential of T1 breast cancer can be predicted by the 70-gene MammaPrint signature. Ann Surg Oncol 17:1406-1413
27. Park YH, Kim ST, Cho EY et al (2010) A risk stratification by hormonal receptors (ER, PgR) and HER-2 status in small (< or = 1 cm) invasive breast cancer: who might be possible candidates for adjuvant treatment? Breast Cancer Res Treat 119:653-661
28. Perez EA, Suman VJ, Davidson NE et al (2011) Sequential versus concurrent trastuzumab in adjuvant chemotherapy for breast cancer. J Clin Oncol 29(34):4491-4497
29. Piccart-Gebhart MJ, Procter M, Leyland-Jones B et al (2005) Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 353:1659-1672
30. Quiet CA, Ferguson DJ, Weichselbaum RR, Hellman S (1995) Natural history of node-negative breast cancer: a study of 826 patients with long-term follow-up. J Clin Oncol 13:1144-1151
31. Railo M, Lundin J, Haglund C, von Smitten K, Nordling S (2007) Ki-67, p53, ER Receptors, Ploidy and S Phase as Long-Term Prognostic Factors in T1 Node-Negative Breast Cancer. Tumor Biol 28:45-51
32. Rodrigues MJ, Wassermann J, Albiges L et al (2010) Trastuzumab treatment in T1ab, node-negative, human epidermal growth factor receptor 2-overexpressing breast carcinomas. J Clin Oncol 28:e541-e542
33. Romond EH, Perez EA, Bryant J et al (2005) Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 353:1673-1684
34. Slamon D, Eiermann W, Robert N et al (2011) Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med 365:1273-1283
35. Theriault RL, Litton JK, Mittendorf EA et al (2011) Age and survival estimates in patients who have node-negative T1ab breast cancer by breast cancer subtype. Clin Breast Cancer 11:325-331
36. Viani GA, Afonso SL, Stefano EJ, De Fendi LI, Soares FV (2007) Adjuvant trastuzumab in the treatment of her-2-positive early breast cancer: a meta-analysis of published randomized trials. BMC Cancer 7:153